



Company Introduction

- **Sichuan Elixir Pharmaceutical Co.,Ltd.**
 - **Focus on natural origin and oncology APIs, setting up R&D and production platform for new salt and crystal form, deep cooperation with clients for IND, NDA, ANDA, 505b(2) or P-IV challenge.**
 - **Explore the potential of macromolecular APIs, setting up R&D and production platform for Glycans and polypeptide.**
 - **Specialized in XDC drugs field, committed to platform building for the innovative research and production on payload and Best-Linker.**
 - **Global registration platform, professional team, and international cGMP system.**
 - **API CMO / CDMO service with global registration.**
 - **Strategy: FDF + APIs.**
 - **Tel: +86-28-89101770 / +86-28-89106518**





➤ **R&D Team**

- **Stable R&D team with over 10 years of experience, more than 20 successful R&D projects.**
- **Synthesis Lab with GRLP standard.**
- **Analysis Lab in accordance with GMP conditions.**
- **In collaboration with well-known universities, focus on new salt, new crystal form and novel technologies, such as synthetic biology and continuous-flow synthetic.**

➤ **Contact**

Tel: +86-28-89101770 / +86-28-89106518

Email: sales@elixir-pharm.com

Website: www.elixir-pharm.com

Address: Room 2018/2019, Building M3, Huanhui Commercial Plaza, High-tech Zone, Chengdu,

Sichuan, China. 610041

Production list			
Product	Cas	Status	Specification
Ursodeoxycholic acid	128-13-2	Commercialized	WC / USDMF
Diosmin	520-27-4	Commercialized	WC / CEP / DMF
Troxaerutin	7085-55-4	Commercialized	WC / CEP / DMF
Rutin	153-18-4	Commercialized	CEP / DMF
Cytisine	485-35-8	Commercialized	USDMF
7-Ethyl-10-hydroxycamptothecin	86639-52-3	Commercialized	WC / USDMF
Irinotecan	97682-44-5	Commercialized	DMF
Cabozantinib	849217-68-1	Commercialized	USDMF
Nilotinib	641571-10-0	Commercialized	USDMF
Dasatinib	302962-49-8	Commercialized	USDMF
Methotrexate	59-05-2	Commercialized	USDMF
Exatecan	171335-80-1	R & D	/
Bufalin	465-21-4	R & D	/
Polysulfated Glycosaminoglycans	NA	R & D	/
Leuprolide Mesylate	944347-41-5	R & D	/
Ferric carboxymaltose	9007-72-1	R & D	/
Oxaerutin	NA	R & D	/
Berberine Hydrochloride	633-65-8	R & D	/
Conjugated Estrogen	12126-59-9	R & D	/

Resmetirom	920509-32-6	R & D	/
Acalabrutinib	1420477-60-6	R & D	/
Alectinib	1256580-46-7	R & D	/
Darolutamide	1297538-32-9	R & D	/
Enasidenib	1446502-11-9	R & D	/
Larotrectinib	1223403-58-4	R & D	/
Osimertinib	1421373-66-1	R & D	/
Abemaciclib	1231929-97-7	R & D	/
Niraparib	1038915-60-4	R & D	/
Venetoclax	1257044-40-8	R & D	/
Finerenone	1050477-31-0	R & D	/
Vericiguat	1350653-20-1	R & D	/
Daprodustat	960539-70-2	R & D	/
Fezolinetant	929016-98-8	R & D	/
Etrasimod	1206123-37-6	R & D	/
Dabrafenib+ Trametinib	NA	R & D	/